
Handbook of Dialysis Therapy, 6th Edition
$376.75
- Paperback
944 pages
- Release Date
11 October 2022
Summary
Edited and written by top experts and pioneers in dialysis, Handbook of Dialysis Therapy, 6th Edition provides the entire dialysis team with a comprehensive overview of this growing field. It covers traditional and advanced procedures, what pitfalls to expect and how to overcome them, and how best to treat various patient populations—all with a practical approach that can be directly applied to patient care.
This must-have resource has been updated with the latest cut…
Book Details
| ISBN-13: | 9780323791359 |
|---|---|
| ISBN-10: | 0323791352 |
| Author: | Allen R. Nissenson, Richard N. Fine, Rajnish Mehrotra, Joshua Zaritsky |
| Publisher: | Elsevier - Health Sciences Division |
| Imprint: | Elsevier - Health Sciences Division |
| Format: | Paperback |
| Number of Pages: | 944 |
| Edition: | 6th |
| Release Date: | 11 October 2022 |
| Weight: | 1.63kg |
| Dimensions: | 276mm x 216mm |
What They're Saying
Critics Review
“This book provides an extensive overview of the routine care of dialysis patients, including different types of dialysis as well as how to deal with complications that can arise for dialysis patients.” ©Doody’s Review Service, 2023, Tyler C Sims, MD (University of Kentucky College of Medicine) Doody’s Score: 5 Stars!
About The Author
Allen R. Nissenson
Dr. Richard E. Fine received his Bachelor’s and PhD degrees in Biochemistry from University of California at Berkeley and Brandeis University respectively. He then was a postdoctoral fellow in the laboratory of Francis Crick and Sydney Brenner at the Laboratory of Molecular Biology in Cambridge, U.K. During this period he and his colleague, Dennis Bray provided the first evidence for actin in growing neurons. Dr. Fine became an Assistant Professor of Physiology and Biochemistry at Boston University School of Medicine and demonstrated the existence of actin regulatory molecules, tropomyosin and troponin C in growing neurons, and he subsequently became interested in the role of clathrin coated vesicles in endocytic and exocytic processes in neurons and in other tissues. He also isolated and characterized vasopressin receptors, demonstrated for the first time that a large molecular, transferrin, can cross the blood brain barrier. Our lab in collaboration with Dr. Ken Kosik were the first to show that an antisense oligonucleotide can be used in vivo to block the synthesis of a single protein. Using the rabbit retina we were able to show that an antisense nucleotide against the kinesin mRNA can block the critical role of kinesin in the transport of synaptic vesicles, neuropeptide containing vesicles and vesicles destined for the plasma membrane. In recent years Dr. Fine’s laboratory has focused on the role of the amyloid beta peptide in Alzheimer’s disease especially in brain capillary endothelium. Also he has recently focused on the role of a mutant protein VPS35, a component of the retromer in Parkinson’s and Alzheimer’s diseases. During his career he has received over $25,000,000 in grant funding, have served on both NIH and VA review panels and authored or co-authored over 100 research papers.
Returns
This item is eligible for free returns within 30 days of delivery. See our returns policy for further details.




